Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(12): e28287.
Published online 2011 December 1. doi:  10.1371/journal.pone.0028287
PMCID: PMC3228735

SLO-2 Is Cytoprotective and Contributes to Mitochondrial Potassium Transport

Stuart E. Dryer, Editor


Mitochondrial potassium channels are important mediators of cell protection against stress. The mitochondrial large-conductance “big” K+ channel (mBK) mediates the evolutionarily-conserved process of anesthetic preconditioning (APC), wherein exposure to volatile anesthetics initiates protection against ischemic injury. Despite the role of the mBK in cardioprotection, the molecular identity of the channel remains unknown. We investigated the attributes of the mBK using C. elegans and mouse genetic models coupled with measurements of mitochondrial K+ transport and APC. The canonical Ca2+-activated BK (or “maxi-K”) channel SLO1 was dispensable for both mitochondrial K+ transport and APC in both organisms. Instead, we found that the related but physiologically-distinct K+ channel SLO2 was required, and that SLO2-dependent mitochondrial K+ transport was triggered directly by volatile anesthetics. In addition, a SLO2 channel activator mimicked the protective effects of volatile anesthetics. These findings suggest that SLO2 contributes to protection from hypoxic injury by increasing the permeability of the mitochondrial inner membrane to K+.


Biological systems contain endogenous mechanisms for protection against stress. In particular, protection against ischemia-reperfusion (IR) injury is thought to proceed via opening of mitochondrial K+ channels [1]. Several cardioprotective strategies require such channels, and channel opening alone is sufficient to induce protection [2], [3]. For example, the protection by ischemic preconditioning involves the mitochondrial ATP-sensitive K+ (mKATP) channel and activation of the channel is cardioprotective [2], [3], [4]. Similarly, volatile anesthetics protect the heart against IR injury, in a phenomenon termed “anesthetic preconditioning” (APC) [5], [6]. APC is evolutionarily conserved from C. elegans to mammals [7], and is potentially of clinical importance [6]. The precise mechanisms of APC remain elusive, although mitochondrial Ca2+ activated K+ channels have been proposed as mediators [8]. The canonical cell surface large-conductance, “big” K+ (BK) channel is coded for by the slo-1 gene in worms and by the Kcnma1 (Slo1) gene in mice. Pharmacologic evidence currently favors SLO1 as the mitochondrial BK (mBK) channel necessary for cardioprotection [9], [10].

However, the large-conductance K+ channel gene family also includes Slo2, represented by a single slo-2 gene in worms and by two genes Kcnt1 (Slo2.2/Slack) and Kcnt2 (Slo2.1/Slick) in mice. Slo2 genes are widely expressed [11], [12], [13]. While a third Slo family member, Slo3/Kcnu1, has also been identified, its expression is restricted to mammalian spermatozoa [14]. The aim of this study was to combine the power of C. elegans genetics with mouse heart physiology and isolated mitochondrial assays, to investigate the relative contribution of SLO1 and SLO2 to mBK underlying APC. Here, we present evidence supporting an evolutionarily conserved role for SLO2 in facilitating mitochondrial K+ transport leading to APC.


Full experimental details are in Supporting Information S1.

C. elegans

Strains used in this study include Bristol-N2 (wild-type, WT); NM1968 slo-1(js379)V; LY100 slo-2(nf100)X; VC1819 slo-2(ok2214)X; KWN193 pha-1(e2123)III, him-5(e1490)V rnyEx112 [pKT60 (partial Slo-2: mCherry) recombined in vivo with linear WRM061CF07 fosmid, pCL1 (pha-1+)]; KWN 314 slo-2(nf100)X, pha-1 (e2123ts)III, rnyEx112; KWN 352 pha-1(e2123)III him-5(e1490)V, rnyEx216 [pKT111 (Pslo-2:SLO-2:GFP), pCL1 (pha-1+)]. All mutant alleles were obtained from the C. elegans Genetic Center and were either obtained backcrossed or were backcrossed onto an N2-Bristol background. Single worm PCR genotyping was used to follow the mutant alleles.


Characterization of the mBK channel was performed using male wild-type (WT) C57BL6 mice age 6–8 weeks purchased from The Jackson Laboratory (Bar Harbor, ME). Experiments involving Slo1-/- (KCNMA1-/-) knockout mice were on an FVB background [15]. Mice were genotyped by tail biopsy PCR, as previously described [15]. Male WT and Slo1-/- littermates age 6–8 weeks were used in experiments.

Ethics Statement

All mice were maintained in an AAALAC-accredited pathogen-free barrier facility with food and water available ad libitum. All procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by an Institutional Animal Care and Use Committee (University Committee on Animal Resources (UCAR) protocol 2010–030).

Hypoxic killing and APC of C. elegans

Experiments were performed on chronologically-synchronized populations of young-adult animals. Briefly, adult hermaphrodites were allowed to lay embryos for a period of two hours, and their adult progeny were tested for the ability to be preconditioned by 2% isoflurane or 4 hours of anoxia essentially as described [7].

Isolation of mitochondria and BTC-AM loading

Mitochondria were isolated from C. elegans as previously described [16]. Mitochondria were isolated from mouse hearts as previously described [17]. The mitochondria were incubated with 20 µM BTC-AM and 0.05% Pluronic F-127 for 10 min at room temperature. The final mitochondrial pellet was suspended in 225 µl of the respective isolation medium described in Supporting Information S1 and stored on ice until use, within 1.5 hrs. Protein was determined by the Folin-phenol method [18].

mBK thallium flux assay (Tl+-flux)

Tl+ is a surrogate for K+ and the Tl+-flux assay is widely used in the cellular K+ channel field [19]. Tl+ uptake into mitochondria were measured using a Varian Cary Eclipse spectrofluorometer as previously described [20] by monitoring changes in BTC fluorescence (λex 488 nm, λem 525 nm).

Mouse Langendorff ex-vivo perfused heart

Following anesthesia with avertin, a rodent 3-lead EKG was briefly obtained. A thoracotomy was then performed, and the aorta cannulated in-situ and rapidly transferred to a perfusion apparatus, as previously described [17]. The heart was perfused with Krebs-Henseleit buffer using constant flow and exposed to global ischemia, as detailed in Supporting Information S1. Following experimental protocols, hearts were stained and imaged as previously described to quantitate infarct size [21].


All chemicals were of the highest grade available from Sigma (St. Louis, MO) unless otherwise specified. Iberiotoxin, Charybdotoxin, and Apamin were from EMD Chemicals Group (Darmstadt, Germany); Bepridil and Paxilline were from Enzo Life Sciences International, Inc. (Plymouth Meeting, PA); Bithionol was from TCI America (Portland, OR); BTC-AM, Benzothiazole coumarin acetyoxymethyl ester was from Invitrogen (Carlsbad, CA).


Data presented are mean ± SEM. Statistical significance (P<0.05) between multiple groups was determined using analysis of variance (ANOVA). In whole worm studies, significance (P<0.05) was determined using a paired Student's t-test.


Mouse heart mBK activity is insensitive to loss of Slo1

To investigate the role of Slo isoforms in conferring K+ transport across the mitochondrial inner membrane, a recently developed fluorescent assay [20] was applied to isolated mouse heart mitochondria, in which thallium (Tl+) flux serves as a K+ surrogate. Tl+, unlike K+, is not normally present in the mitochondrial matrix and so does not require depletion prior to the assay. In addition, Tl+ is transported very effectively by K+ channels. In conjunction with transporter-specific pharmacologic signatures, this technique allows for assessment of pathways that contribute to mitochondrial K+ transport. For example, we demonstrated previously that mKATP channels contribute to Tl+ flux [20].

The mBK is a critical component of APC-mediated cardioprotection [8], and to date the Slo1 gene product has been thought to underlie mBK activity [9], [10]. Under conditions where ATP was present to block mKATP channels, we observed mitochondrial Tl+ flux that was activated by bithionol and inhibited by paxilline (Figure 1A), consistent with a BK channel activity [11], [22]. However, Tl+ flux was not affected by iberiotoxin, charybdotoxin or apamin (Figure 1A). Apamin is specific for small-conductance K+ channels, and so this result was not surprising. However, charybdotoxin and iberiotoxin are thought to target the canonical BK channel Slo1, which is voltage and calcium-activated. In light of this observation, we also tested the ability of Ca2+ to activate the Tl+ transport activity and found it to be ineffective (Figure 1A). Such Ca2+ insensitivity has been previously reported for cardiac mitochondrial K+ fluxes [23]. Finally, we found that bepridil, which targets voltage activated Ca2+ channels and KNa channels [22], inhibited mBK (Figure 1A). Paxilline, Ca2+, and bepridil did not disrupt the membrane potential (Table S1).

Figure 1
Mouse heart mBK channel activity is independent of Slo1.

Based on these observations, we obtained a mouse strain containing the Kcnma1tm1Rwa allele targeting Slo1 (referred to hereafter as Slo1-/-) [15] and investigated mBK activity (biothionol-activated Tl+ transport with the above described pharmacologic sensitivities) in purified heart mitochondria. The results (Figure 1B) show an identical mBK activity and pharmacologic profile in both Slo1-/- and control wild-type (WT) littermates, suggesting mBK is not Slo1-derived.

Anesthetic preconditioning of perfused mouse hearts is insensitive to loss of Slo1

Since mBK is thought to contribute to APC, we next tested whether Slo1 contributes to protection against IR injury by the volatile anesthetic isoflurane. APC protection was measured in ex-vivo perfused hearts from Slo1-/- mice and control WT littermates. As previously reported [24], Slo1-/- mice exhibited a slightly lower heart rate (Table S2). Nevertheless, both strains exhibited identical sensitivity to baseline IR injury (infarct size, and recovery of rate x pressure product) (Figure 2 and Table S3). Furthermore, no difference in APC-induced protection was observed between Slo1-/- and WT hearts (Figure 2 and Table S3), suggesting that protection by APC is SLO1-independent. Moreover, protection by ischemic preconditioning (IPC) was preserved in Slo1-/- mice (Figure S1 and Table S3). Although these results suggest that SLO1 channel activity is not necessary for APC or IPC, they do not negate the idea that SLO1 may be an important pharmacologic target for cardioprotection, or may be involved in other protective mechanisms [9].

Figure 2
APC in mouse hearts is independent of Slo1.

We note that APC-induced cardioprotection was ablated by paxilline in both the Slo1-/- and WT hearts (Figure 2), though paxilline alone had no effect on baseline IR injury (Figure S2). This data suggests that an alternate paxilline-sensitive transporter might be involved in APC. The SLO3 channel is unlikely to account for the observed K+ transport activity as it is relatively insensitive to paxilline [25] and its expression is restricted to testes. On the other hand, both the Slo2.1 (Slick) and Slo2.2 (Slack) mammalian Slo2 paralogues are widely expressed. Furthermore, they have been shown to be Ca2+ insensitive [26], [27], [28], which is in agreement with the mitochondrial Tl+ flux data (Figure 1).

SLO2 channels are instead activated by Na+, and while this would be an intriguing characteristic to test, using Na+ to stimulate Tl+ uptake is problematic as Na+ affects mitochondrial function. Initial experiements with cardiac sub-cellular protein fractions revealed an immuno-reactive band in the mitochondria using both anti-Slo2.1 and anti-Slo2.2 antibodies that was close to the predicted molecular weights of Slo2.1 and Slo2.2 proteins (Figure S3). The presence of additional bands in cardiac homogenates, however, precluded the use of these antibodies for immunohistochemical protein localization in fixed tissues. Likewise, using genetics to test the role of SLO2 in mice is complicated by the fact that, unlike Slo1 (and Slo3), neither of the Slo2 deletion strains have yet been reported. For this reason, we turned to the genetic model organism C. elegans.

The slo-2 gene product contributes to anesthetic preconditioning in C. elegans

APC is known to protect the nematode C. elegans from subsequent hypoxic death [7], and worm orthologs of Slo1 and Slo2 exist. Further simplifying the use of this model is the fact that the worm slo-2 gene has not diverged into Slo2.1 and Slo2.2 paralogs. Since loss-of-function mutants of both slo-1 and slo-2 are viable in worms, to determine which gene products are required for APC, these mutants were tested for their ability to be preconditioned by isoflurane. As shown in Figure 3A, APC significantly improved the resistance of both wild-type (WT) and slo-1 ablated worms to hypoxic stress. This result matched our findings with the mouse Slo1 knockout model (Figure 2). However, the loss of slo-2 largely blocked protection by APC (Figure 3A). These results were confirmed by using a second distinct slo-2 mutant allele (Table S4). We further demonstrated that reintroducing the native slo-2 gene (contained in the WRM061CF07 fosmid) into the slo-2 mutant could restore the beneficial effects of APC (Figure 3B). A transgenic fusion of SLO-2 to either mCherry or GFP (Figure 3C–F) was unable to rescue the mutant (data not shown), suggesting that the “tagged” protein is either non-functional or does not localize correctly. Remarkably, all strains were protected by IPC (Figure S4) emphasizing the specificity of slo-2 for APC-mediated protection.

Figure 3
APC in C. elegans requires slo-2.

Unlike several recently identified transporters whose activity is restricted to the mitochondrial inner membrane [29], [30], [31] SLO-2 was not expected to localize to the mitochondria exclusively. As has been pointed out for the mKATP channel [32], there may only be a few molecules per mitochondrion, particularly given SLO2's large unitary conductance, and confocal analysis of the SLO-2 fluorescent protein fusions indicated mainly plasma membrane localization (data not shown). In short, while these results confirmed that SLO2 contributes to effective APC in the worm model, they did not rule out a role for a plasma membrane, rather than mitochondrial, conductance in this process. This prompted us to investigate the role of Slo isoforms in conferring K+ transport across the mitochondrial inner membrane in worms more directly.

mBK channel activity C. elegans requires slo-2

mBK activity was measured in isolated C. elegans mitochondria using the same Tl+ flux assay described above for mouse mitochondria [16]. C. elegans mitochondria exhibited an ATP-insensitive Tl+ flux that was activated by the BK agonist bithionol, insensitive to the mKATP blockers 5-hydroxydecanoate and glyburide, and blocked by the BK channel inhibitor paxilline and by bepridil (Figure 4). Both paxilline and bepridil did not decrease the Tl+ flux signal below the signal of ATP alone (ATP+Pax, 57.8±13.1; ATP+Bep, 51.7±11.4). These pharmacologic properties fit the profile of a classical BK channel [33], [22], [34]. Interestingly, unlike in mice, Ca2+ was capable of activating the mBK in worms (Figure 4); the slo-2 gene product in worms is sensitive to Ca2+ [35]. Notably, the C. elegans mBK was insensitive to the SLO-1 inhibitors iberiotoxin and charybdotoxin as well [11], [12].

Figure 4
Pharmacologic characteristics of C. elegans mBK channel activity in the wildtype N2-Bristol strain.

Measuring mBK activity in mitochondria from WT, slo-1 and slo-2 mutants (Figure 5) revealed that only loss of slo-2 abolished bithionol-stimulated Tl+ flux. This effect could not be attributed to a general effect on mitochondrial function, since mKATP channel activity was not different between strains. Overall, these data suggest that slo-2 expression contributes to both mBK conductance and APC in C. elegans, while slo-1 is dispensable for both.

Figure 5
C. elegans mBK channel activity requires slo-2.

The mBK channel is activated by isoflurane, and pharmacologic channel activation is sufficient to elicit hypoxic protection

Currently there is no evidence for mBK activation by volatile anesthetics. In Figure 6 we demonstrate that isoflurane caused an increase in Tl+ flux through the mitochondrial inner membrane in both mice and worms. The pharmacologic characteristics of the Tl+ transport activity are identical to those observed for the bithionol-activated channel in both species (i.e., blocked by paxilline and bepredil). Furthermore, isoflurane-stimulated channel activity was ablated in mitochondria from slo-2 mutant worms (Figure 6B).

Figure 6
Isoflurane activation of mBK channel activity in mouse and C. elegans.

Finally, although our results suggest that Slo2 channel opening by volatile anesthetics is necessary for full protection by APC, we wanted to determine whether channel opening is sufficient to recapitulate the protective effect of APC. Thus, the pharmacologic BK activator bithionol was tested for its ability to protect hearts from IR injury in the mouse heart perfusion model. The data indicate that bithionol pre-treatment elicits significant protection as reflected by reduced infarct size, and enhanced recovery of rate x pressure product (Figure 7). Moreover, the protection afforded by bithionol pretreatment was retained in Slo1-/- hearts (Figure 7), confirming that the SLO1 channel is not the physiologic target of bithionol that elicits protection. These data suggest that opening of a BK channel, most likely mitochondrial and derived from Slo2, is both necessary and sufficient for cardioprotection from ischemia.

Figure 7
Cardioprotection by the BK activator bithionol.


Several mitochondrial K+ channel sub-types have been implicated in protection against ischemic injury [1], yet to date all such channels remain undefined at the molecular level. Overall, the unique combination of genetics and pharmacologic signatures studied herein are consistent with a conclusion that SLO2 underlies mBK activity and APC-induced protection in both C. elegans and perhaps in mouse hearts, as well.

While the mBK channel in both C. elegans and mouse mitochondria displayed similar pharmacological profiles, only the C elegans channel was activated by Ca2+. These results are consistent with the observation that C elegans SLO-2 channels are activated by Ca2+, while the mammalian Slo2 ortholog is instead activated by Na+ [28], [26], and support the hypothesis that the mBK necessary for mitochondrial K+ transport and APC is derived from SLO2 in both C elegans and mice. It is interesting that C. elegans lack a voltage-gated Na+ channel [36]. The differing ion-sensitivities between mammals and C. elegans Slo2 channels may reflect underlying differences in ischemic electrolyte handling [26], and in this respect, it is noteworthy that the Slo2 channel characteristics appear to reflect this divergence.

It is not yet clear which mammalian SLO2 paralogue may constitute the mBK channel. In fact, both SLO2.1 and SLO2.2 may play important roles, since the optimal sub-cellular localization of each paralogue appears to depend on formation of heteromers with the other [37], [12]. Unfortunately, there are currently no pharmacologic tools to distinguish between SLO2.1 and SLO2.2, and although SLO2.1 is blocked by ATP [11] this effect is overridden by pharmacologic channel activators (similar to mKATP[38], [20]), and it is not known how SLO2 heteromer formation impacts ATP sensitivity.

While in C. elegans slo-2 was not necessary for protection by IPC, from the perspective of ischemia however, we find it interesting that SLO2.2 is activated by hypercapnia and acidosis [27] both which protect against IR injury [39], [40], [41]. Of particular interest is the role of acidosis in activating SLO2 since alkalinization of the matrix is a result of an open mitochondrial K+ channel [42] and represents a possible mechanism of feedback inhibition. Likewise, the observation that both SLO2.1 and SLO2.2 channels exhibit KNa activity [11], [27] may have implications for mammalian mBK channel activity during ischemia, in which intracellular Na+ is elevated [43], [44]. These commonalities may warrant further investigation into the role of SLO2.1 and SLO2.2 in IPC in a mammalian context.

It is clear from our data that SLO1 is not required for either APC or IPC in worms or in mice. However, our results do not preclude the presence of SLO1 in the mitochondria or a role for SLO1 channels in other protective paradigms. In fact, the Slo family of K+ channels exhibits a wide diversity of auxiliary subunits and multimeric assemblies in different tissues [37], yielding diverse activities, ion/second-messenger sensitivities, and roles in cellular processes [26]. In particular, SLO1 and SLO2.2 can heteromultimerize yielding a channel with intermediate properties [12]. For example, SLO1 channel is sensitive to iberiotoxin and SLO2.2 is insensitive to Ca2+ but a SLO1/SLO2.2 heteromultimer channel is insensitive to iberiotoxin and sensitive to Ca2+ [12]. Thus, the tissue diversity in BK composition may explain previous pharmacology-based studies suggesting a Slo1-derived mBK in other tissues [10]. Similarly, slo-1 in worms is known to regulate neurotransmitter release at the synaptic junction [45] where it acts upstream or parallel to syntaxin [46]. Mutants in either of these genes can alter the effect of anesthetics on behavior [46]. It is possible that slo-1 acting through this pathway could indirectly affect mitochondrial function through humoral neurosecretory mechanisms. However, our unpublished results confirm observations that syntaxin mutants, like slo-1 mutants, are nevertheless able to be effectively preconditioned by isofluorane [7].

While it is possible that mBK activation may occur directly through anesthetic stimulation, and we have demonstrated that mBK in isolated mitochondria are opened by isofluorane (Figure 6), it is also possible that activation occurs indirectly via other anesthetic targets such as protein kinases that may co-purify with mitochondria [8], [47], [48]. Such activation would then stimulate mitochondrial K+ uptake, with subsequent protection from ischemia occurring via downstream mechanisms that are not yet clear. The activation of mitochondrial K+ channels is proposed to mediate protection via the regulation of the mitochondrial matrix volume, decreasing mitochondrial Ca2+ uptake and modulating reactive oxygen species generation [4]. Through these events activation of the mBK might block the formation of the mitochondrial permeability transition pore and subsequent cell death [4].

In conclusion, the slo-2 gene in worms contributes to a K+ influx pathway at the mitochondrial inner membrane with a nearly identical pharmacologic sensitivity to a repertoire of activators and inhibitors as recombinant SLO2 channels. Furthermore, slo-2 is necessary for APC-induced protection in worms. Conversely, SLO1 does not contribute to the mitochondrial K+ influx pathway studied here, nor is it required for APC or IPC in either worms or mice. We hypothesize that given these results, Slo2 is likely the APC-relevant channel in mice, and our results further suggest that pharmacologic opening of Slo2 elicits protection. These results have the potential to refocus the design of anti-ischemic therapeutics.

Supporting Information

Figure S1

IPC in mouse hearts is independent of Slo1. Perfused hearts were subjected to IR injury (from Figure 2) or ischemic preconditioning (IPC)+IR, as outlined in Supporting Information S1 methods. (A) Left-ventricular function (heart rate x pressure product, RPP) was monitored throughout, and is expressed as % of initial value. Data for WT (white symbols) and Slo1-/- (gray symbols) FVB littermates are shown on separate axes for clarity. (B) Upon completion of IR protocols, hearts were sliced, fixed and stained with tetrazolium chloride, to delineate live (red) and infarcted (white) tissue. Upper panel shows typical slices used for quantitation of infarct area. Lower panel shows infarct expressed as a percent of the area at risk (100% in this global ischemia model). All data are means ± SEM, N≥4 (N = independent hearts).*p<0.05 vs. IR.


Figure S2

Paxilline in mouse hearts does not affect ischemic sensitivities. Perfused hearts were subjected to IR injury (from Figure 2) or paxilline (Pax)+IR, as outlined in Supporting Information S1 methods. (A) Left-ventricular function (heart rate x pressure product, RPP) was monitored throughout, and is expressed as % of initial value. Data for WT (white symbols) and Slo1-/- (gray symbols) FVB littermates are shown on separate axes for clarity. (B) Upon completion of IR protocols, hearts were sliced, fixed and stained with tetrazolium chloride, to delineate live (red) and infarcted (white) tissue. Upper panel shows typical slices used for quantitation of infarct area. Lower panel shows infarct expressed as a percent of the area at risk (100% in this global ischemia model). All data are means ± SEM, N = 5 (N = independent hearts).


Figure S3

Immunoblot analysis of SLO2 in fractionated cardiac tissue. Homogenate from WT (C57BL/6) mouse hearts was fractionated and the proteins were separated by SDS-PAGE. Slo2.1 and Slo2.2 were detected by immunoblot analysis (NeuroMab antibodies), as detailed in Supporting Information S1 methods. Western blots for GAPDH, adenine nucleotide translocator 1 (ANT1) and histones validated separation of the homogenate into cytosolic, mitochondrial and nuclear fractions, respectively.


Figure S4

IPC in C. elegans is independent of slo-1 and slo-2. WT, slo-1(js379) and slo-2(nf100) mutants were subjected to hypoxia-reoxygenation (HR) and ischemic preconditioning IPC+HR, as detailed in the methods section of Supporting Information S1. Viability is expressed as percent of dead worms. Means ± SEM, N = 4 (N = independent trials of >100 worms per trial), *p<0.05 vs. HR.


Table S1

Mitochondrial membrane potential is not affected by channel modulators. Mitochondria were isolated from WT (C57BL/6) mice and loaded with a fluorescent indicator (TMRE 20 nM or JC-1 0.2 µg/mL) in the presence of either Bithionol (2.5 µM), CaCl2 (25 µM), Paxilline (1 µM) or Bepridil (10 µM). Fluorescent indicators accumulate in mitochondria in relation to membrane potential (Δψm). Following stabilization, Δψm was collapsed via addition of Δψm FCCP (10 µM) resulting in a re-distribution of the fluorescent indicator, resulting in a decrease in fluorescence. All data are means ± SEM, N≥3 and are not significantly different (N = independent mitochondria isolation of ≥3 mouse hearts).


Table S2

EKG parameters of Avertin anesthetized wild-type (WT) and Slo1-/- littermate FVB mice. EKG was collected as outlined in the methods. All data are means ± SEM, N≥13 *p<0.05 vs. WT.


Table S3

Mouse langendorff functional parameters. Groups are indicated in the left column in both wild-type (WT, top table) and Slo1-/- (bottom table) FVB littermates. Parameters (indicated in the top row) were measured at the time points indicated. LVDP, left ventricular developed pressure (% of control). Data are means ± SEM, N≥4 *p<0.05 vs. IR (60 min Reperfusion). †p<0.05 vs. APC+IR (60 min Reperfusion).


Table S4

APC-dependent protection in C. elegans requires slo-2. C. elegans WT control (N2-Bristol), slo-1(js379)V, slo-2(nf100)X, and slo-2(ok2214)X mutants were subjected to hypoxia-reoxygenation (HR) and isoflurane APC+HR, as detailed in the methods section of Supporting Information S1, and the average reduction in % death was determined. Means ± SEM. N2, N = 28; slo-1(js379), N = 12; slo-2(nf100), N = 27; slo-2(ok2214), N = 4. (N = independent trials of >100 worms per trial).


Supporting Information S1

Supplementary methods.



We thank James Melvin (NIH) and Richard Aldrich (University of Texas at Austin) for the Slo1-/- mice.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported in part by an American Heart Association, Founder Affiliate Postdoctoral Fellowship award 11POST7290028 (to APW), and by US National Institutes of Health grants HL071158 (to PSB), GM087483 (to PSB & KWN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. O'Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004;94:420–432. [PMC free article] [PubMed]
2. Costa AD, Garlid KD. MitoKATP activity in healthy and ischemic hearts. J Bioenerg Biomembr. 2009;41:123–126. [PubMed]
3. Wojtovich AP, Brookes PS. The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Basic Res Cardiol. 2009;104:121–129. [PMC free article] [PubMed]
4. Facundo HT, Fornazari M, Kowaltowski AJ. Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta. 2006;1762:202–212. [PubMed]
5. De Hert SG, Turani F, Mathur S, Stowe DF. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg. 2005;100:1584–1593. [PubMed]
6. Riess ML, Stowe DF, Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol. 2004;286:H1603–H1607. [PubMed]
7. Jia B, Crowder CM. Volatile anesthetic preconditioning present in the invertebrate Caenorhabditis elegans. Anesthesiology. 2008;108:426–433. [PubMed]
8. Redel A, Lange M, Jazbutyte V, Lotz C, Smul TM, et al. Activation of mitochondrial large-conductance calcium-activated K+ channels via protein kinase A mediates desflurane-induced preconditioning. Anesth Analg. 2008;106:384–91table. [PubMed]
9. Xu W, Liu Y, Wang S, McDonald T, Van Eyk JE, et al. Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science. 2002;298:1029–1033. [PubMed]
10. Siemen D, Loupatatzis C, Borecky J, Gulbins E, Lang F. Ca2+-activated K channel of the BK-type in the inner mitochondrial membrane of a human glioma cell line. Biochem Biophys Res Commun. 1999;257:549–554. [PubMed]
11. Bhattacharjee A, Joiner WJ, Wu M, Yang Y, Sigworth FJ, et al. Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP. J Neurosci. 2003;23:11681–11691. [PubMed]
12. Joiner WJ, Tang MD, Wang LY, Dworetzky SI, Boissard CG, et al. Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits. Nat Neurosci. 1998;1:462–469. [PubMed]
13. Yuan A, Santi CM, Wei A, Wang ZW, Pollak K, et al. The sodium-activated potassium channel is encoded by a member of the Slo gene family. Neuron. 2003;37:765–773. [PubMed]
14. Schreiber M, Wei A, Yuan A, Gaut J, Saito M, et al. Slo3, a novel pH-sensitive K+ channel from mammalian spermatocytes. J Biol Chem. 1998;273:3509–3516. [PubMed]
15. Meredith AL, Thorneloe KS, Werner ME, Nelson MT, Aldrich RW. Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel. J Biol Chem. 2004;279:36746–36752. [PubMed]
16. Wojtovich AP, Burwell LS, Sherman TA, Nehrke KW, Brookes PS. The C. elegans mitochondrial K+(ATP) channel: a potential target for preconditioning. Biochem Biophys Res Commun. 2008;376:625–628. [PMC free article] [PubMed]
17. Nadtochiy SM, Burwell LS, Ingraham CA, Spencer CM, Friedman AE, et al. In vivo cardioprotection by S-nitroso-2-mercaptopropionyl glycine. J Mol Cell Cardiol. 2009;46:960–968. [PMC free article] [PubMed]
18. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275. [PubMed]
19. Weaver CD, Harden D, Dworetzky SI, Robertson B, Knox RJ. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen. 2004;9:671–677. [PubMed]
20. Wojtovich AP, Williams DM, Karcz MK, Lopes CM, Gray DA, et al. A Novel Mitochondrial KATP Channel Assay. Circ Res. 2010;106:1190–1196. [PMC free article] [PubMed]
21. Nadtochiy SM, Redman E, Rahman I, Brookes PS. Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res. 2011;89:643–649. [PMC free article] [PubMed]
22. Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, et al. Pharmacological activation and inhibition of Slack (Slo2.2) channels. Neuropharmacology. 2006;51:896–906. [PubMed]
23. Cancherini DV, Queliconi BB, Kowaltowski AJ. Pharmacological and physiological stimuli do not promote Ca(2+)-sensitive K+ channel activity in isolated heart mitochondria. Cardiovasc Res. 2007;73:720–728. [PubMed]
24. Imlach WL, Finch SC, Miller JH, Meredith AL, Dalziel JE. Vol. 5. PLoS One; 2010. A role for BK channels in heart rate regulation in rodents. [PMC free article] [PubMed]
25. Zhou Y, Tang QY, Xia XM, Lingle CJ. Glycine311, a determinant of paxilline block in BK channels: a novel bend in the BK S6 helix. J Gen Physiol. 2010;135:481–494. [PMC free article] [PubMed]
26. Salkoff L, Butler A, Ferreira G, Santi C, Wei A. High-conductance potassium channels of the SLO family. Nat Rev Neurosci. 2006;7:921–931. [PubMed]
27. Ruffin VA, Gu XQ, Zhou D, Douglas RM, Sun X, et al. The sodium-activated potassium channel Slack is modulated by hypercapnia and acidosis. Neuroscience. 2008;151:410–418. [PubMed]
28. Bhattacharjee A, Kaczmarek LK. For K+ channels, Na+ is the new Ca2+. Trends Neurosci. 2005;28:422–428. [PubMed]
29. Perocchi F, Gohil VM, Girgis HS, Bao XR, McCombs JE, et al. MICU1 encodes a mitochondrial EF hand protein required for Ca(2+) uptake. Nature. 2010;467:291–296. [PMC free article] [PubMed]
30. Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature. 2011. [PMC free article] [PubMed]
31. De SD, Raffaello A, Teardo E, Szabo I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature. 2011. [PubMed]
32. Wojtovich AP, Nehrke KW, Brookes PS. The mitochondrial complex II and ATP-sensitive potassium channel interaction: quantitation of the channel in heart mitochondria. Acta Biochim Pol. 2010;57:431–434. [PubMed]
33. Meera P, Wallner M, Toro L. A neuronal beta subunit (KCNMB4) makes the large conductance, voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and iberiotoxin. Proc Natl Acad Sci U S A. 2000;97:5562–5567. [PubMed]
34. Yang B, Desai R, Kaczmarek LK. Slack and Slick K(Na) channels regulate the accuracy of timing of auditory neurons. J Neurosci. 2007;27:2617–2627. [PubMed]
35. Yuan A, Dourado M, Butler A, Walton N, Wei A, et al. SLO-2, a K+ channel with an unusual Cl- dependence. Nat Neurosci. 2000;3:771–779. [PubMed]
36. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science. 1998;282:2028–2033. [PubMed]
37. Chen H, Kronengold J, Yan Y, Gazula VR, Brown MR, et al. The N-terminal domain of Slack determines the formation and trafficking of Slick/Slack heteromeric sodium-activated potassium channels. J Neurosci. 2009;29:5654–5665. [PubMed]
38. Jaburek M, Yarov-Yarovoy V, Paucek P, Garlid KD. State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem. 1998;273:13578–13582. [PubMed]
39. Luo H, Chang Y, Cai H, Zou W, Wang D et al. The effect of hypercapnic acidosis preconditioning on rabbit myocardium. J Huazhong Univ Sci Technolog Med Sci. 2008;28:706–710. [PubMed]
40. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115:1895–1903. [PubMed]
41. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol. 2007;102:445–452. [PubMed]
42. Garlid KD, Paucek P. The mitochondrial potassium cycle. IUBMB Life. 2001;52:153–158. [PubMed]
43. Murphy E, Eisner DA. Regulation of intracellular and mitochondrial sodium in health and disease. Circ Res. 2009;104:292–303. [PMC free article] [PubMed]
44. Pike MM, Kitakaze M, Marban E. 23Na-NMR measurements of intracellular sodium in intact perfused ferret hearts during ischemia and reperfusion. Am J Physiol. 1990;259:H1767–H1773. [PubMed]
45. Wang ZW, Saifee O, Nonet ML, Salkoff L. SLO-1 potassium channels control quantal content of neurotransmitter release at the C. elegans neuromuscular junction. Neuron. 2001;32:867–881. [PubMed]
46. Hawasli AH, Saifee O, Liu C, Nonet ML, Crowder CM. Resistance to volatile anesthetics by mutations enhancing excitatory neurotransmitter release in Caenorhabditis elegans. Genetics. 2004;168:831–843. [PubMed]
47. Zhou XB, Wulfsen I, Utku E, Sausbier U, Sausbier M, et al. Dual role of protein kinase C on BK channel regulation. Proc Natl Acad Sci U S A. 2010;107:8005–8010. [PubMed]
48. Lamberts RR, Onderwater G, Hamdani N, Vreden MJ, Steenhuisen J, et al. Reactive oxygen species-induced stimulation of 5′AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation. 2009;120:S10–S15. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science